Dr. Chim Chor Sang James - Haematology & Haematological Oncology
Specialist in Haematology & Haematological Oncology
Highlights
- MCHK RegisteredVerified
- 2 LocationsJardine's Lookout · Pok Fu Lam
- Specialist in Haematology & Haematological OncologyBachelor of Medicine and Bachelor of Surgery (MBChB) · Doctor of Medicine (MD) · Doctor of Philosophy (PhD) · Medical degree 1986
- InsuranceBeing compiled｜See details
About
Dr. Chim Chor Sang James practises Haematology & Haematological Oncology in Jardine's Lookout and Pok Fu Lam, Hong Kong.
Education
Specialist in Haematology & Haematological Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBChB)Bachelor of Medicine and Bachelor of Surgery (MBChB)1986
- Doctor of Medicine (MD)Doctor of Medicine (MD)
- Doctor of Philosophy (PhD)Doctor of Philosophy (PhD)
- Member of the Royal Colleges of Physicians of the United KingdomMember of the Royal Colleges of Physicians of the United Kingdom
Hong Kong Academy of Medicine fellowships
- FHKCPFellow, Hong Kong College of Physicians
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Locations
Hong Kong Sanatorium & Hospital
2 Village Road, Happy Valley, Hong Kong
Get Directions →Jardine's Lookout
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Chim Chor Sang James? Claim page and update insurance →
FAQ
Is Dr. Chim Chor Sang James any good?
Dr. Chim Chor Sang James practises Haematology & Haematological Oncology in Jardine's Lookout and Pok Fu Lam, Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Chim Chor Sang James do?
Dr. Chim Chor Sang James practises in Haematology & Haematological Oncology.
Where does Dr. Chim Chor Sang James practise?
Dr. Chim Chor Sang James practises at Hong Kong Sanatorium & Hospital, Pok Fu Lam.
Are you Dr. Chim Chor Sang James? Claim this page to update and manage.
ClaimResearch and publications
61 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.Clinical hematology international · 2026
- Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.Annals of hematology · 2025
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025
- Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.Annals of hematology · 2025
- Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).Blood cancer journal · 2025
- Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.Bone marrow transplantation · 2024
- Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.Annals of hematology · 2024
- Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.Clinical lymphoma, myeloma & leukemia · 2023
- The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.Therapeutic advances in hematology · 2022
- Epigenetic Silencing of Tumor Suppressor lncRNA <i>NKILA</i>: Implication on NF-κB Signaling in Non-Hodgkin's Lymphoma.Genes · 2022
- miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.Cell communication and signaling : CCS · 2021
- Case series: MRD negativity assessment using <sup>11</sup>C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.Therapeutic advances in hematology · 2021
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
Elsewhere on the web
Hospital pages
These links are matched automatically by the doctor's name and are not confirmed by the doctor. Names repeat in Hong Kong — open a link to check.
For reference only. Not medical advice. Read full disclaimer